Prostate cancer
Conditions
Interventions
Group A:Administer 68Ga-FC516 injection and perform PET/CT imaging
Group B:Administer 68Ga-FC516 and 68Ga-PSMA11 or 68Ga-OnCoACP3 injections, and perform PET/CT imaging.
Sponsors
The First Affiliated Hospital, Jinan University
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.The subjects voluntarily signed the informed consent form and were able to complete the trial as per the protocol requirements. 2.Age: 18 years old and above; 3.Group A: Healthy subjects; Group B: Patients diagnosed with prostate cancer through pathological tissue or cytological examination; 4.If the patient with prostate cancer has tissue samples, the samples need to be provided for the assessment of ACP3 expression. 5.Qualified patients with reproductive capacity must agree to use a reliable contraceptive method (hormonal, barrier, or abstinence) with their partners during the trial period and for at least 3 months after the last medication administration.
Exclusion criteria
Exclusion criteria: 1.Those with severe liver, kidney and heart dysfunction; 2.Patients with severe obesity and those who cannot or are unable to undergo PET/CT scans; 3.Allergic to any active or inactive ingredients of the studied drug; 4.Other researchers consider the subjects who are not suitable for inclusion in the study; 5. Underwent major organ surgery (excluding biopsy) or experienced significant trauma within 4 weeks prior to the first dose, or requires elective surgery during the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV value; | — |
Secondary
| Measure | Time frame |
|---|---|
| Residence time; | — |
Countries
China
Contacts
Public ContactLu Wang
The First Affiliated Hospital, Jinan University
Outcome results
None listed